Sacubitril + Valsartan

This combination is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

This combination is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.

There are no products to list in this category.

Continue